Skip to main content
. 2018 May 4;9(34):23373–23389. doi: 10.18632/oncotarget.25169

Figure 2. Anticonvulsant effect of fenfluramine and S1RA in a mouse model of seizures induced by NMDAR over activation.

Figure 2

(A) Behavioral alterations produced by icv administration of NMDA to mice pretreated (–24 h) with the opioid agonist morphine (10 nmol, icv). (B) Effects of S1RA, fenfluramine and norfenfluramine (3 nmol each, icv) on seizures induced by NMDA (300 pmol, icv) in morphine-primed mice. The drugs were injected icv 30 min before the administration of the NMDA receptor agonist. *Significant difference from the control group, which received morphine and 24 h later NMDA, but saline instead of treatment; ϕ indicates that 3 nmol icv PPCC or 3 nmol icv 4F 4PP prevented the diminishing effects of S1RA/fenfluramine/norfenfluramine on the corresponding NMDA-induced behavioral sign. (C) Effects of the treatments on the latency and duration of the seizure episodes. *Significant difference from the control group receiving saline. ANOVA, Dunnett multiple comparisons vs control group, p < 0.05. (A–C) Each bar indicates the percentage of mice showing the indicated sign and represents the mean ± SEM of 9 mice.